Danaher Corporation · NYSE:DHR
Danaher — Conference Presentation (January 2022)
8 slides from Danaher's conference presentation, Jan 11, 2022
Slide 1: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur are "forward-looking"
Slide 2: Reconciliation of GAAP to Non-GAAP Financial Measures
DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES Core Sales Growth, Core Sales Growth Including Cytiva and Base Business Core Sales Growth % Change Three. Month Period Ended _% Change Year _ Change Year _% Change Yea December 31,2021 Ended December SI, Ended December 31, Fad
Slide 3: Current Update: Strong finish to 2021
Current Update 3 Strong finish to 2021 Q4 2021 RESULTS EXCEEDED OUR EXPECTATIONS Q4 2021 ESTIMATED CORE REVENUE GROWTH UP HIGH-TEENS — All three segments better-than-expected, led by Life Sciences and Diagnostics — Performance driven by our base business which was up ~10% — Better-than-expected reve
Slide 4: Danaher Today: Purpose-driven science & technology leader
~$29B 2021E TOTAL REVENUE LIFE SCIENCES ~$14.9B DIAGNOSTICS ~$9.8B ENV. & APPLIED ~$4.7B Danaher Today Purpose-driven science & technology leaderAll financial metrics reflect FY 2021E results 4
Slide 5: Purpose-Driven Portfolio Transformation
LS 51% Dx 33% EAS 16% T&M 13% LS 33% Dental 14% Dx 31% EAS 22% 2018 2021E LS & Dx 40% Dental 13% T&M 13% Env. 18% Ind. 16% 2015 Purpose-Driven Portfolio Transformation Portfolio has evolved meaningfully2015 metrics shown include Fortive and Envista; 2018 metrics shown include Envista. Pie charts are
Slide 6: Portfolio Transformation: A Stronger, Better Danaher
CORE REVENUE GROWTH ~$4B ~$8B ~17% >25% ~45% ~75% +LSD +Low Teens Portfolio Transformation: A Stronger, Better Danaher Focus on growth & business model driving superior performance RECURRING REVENUE 2015 2019- 21E 2015 2021E 2015 2021E 2015 2021E OPERATING PROFIT MARGIN OPERATING CASH FLOW 6 2015 me
Slide 7: Differentiated Positioning in Bioprocessing
Differentiated Positioning in Bioprocessing Concentration & Sterile Filtration Filtration Skids & Consumables Media Bioreactor Depth Filter Chromatography Columns Polishing Column Devices Bags & Mixers DHR well-positioned across bioprocessing with ~$7.5B portfolio Cell culture & SUT Chromatography F
Slide 8: Putting It All Together
Putting It All Together 8 DANAHER MSD+ 100bps+ acceleration vs pre-2019 HSD ~$6B 2021E revenue (2x vs acq.) LDD ~$3.5B 2021E revenue (>10% of DHR) Durable long-term testing oppty. REST OF DANAHER MSD+ Benefit from continued investment spend CORE REVENUE GROWTH MSD+ OPERATING MARGIN EXPANSION 50-75BP